Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

  • Marchal, Astrid
  • COVID Clinicians
  • Bolze, Alexandre
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B∗15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the United States (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B∗15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections studied, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer's Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (Equation 201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 101057100 (UNDINE), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of business in EMEA, and the General Atlantic Foundation, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. A.N.S. is supported by European Union’s Horizon Health research and innovation program under grant agreement No. 101057100, project UNDINE. S.G.T. is supported by an Investigator Grant awarded by the National Health and Medical Research Council of Australia, and a University of New South Wales Sydney COVID Rapid Response Initiative grant. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 10101616. The French COVID Cohort study group was sponsored by Inserm and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, European Commission (Grant RECOVER WP 6). The COVIDeF study group was supported by the French Ministry of Health and Fondation AP-HP Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0048). Y.Z. is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. This project has received funding from the Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959), the Swiss National Science Foundation (grant # 310030L_197721 to J.F.), and ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grants AJF202019 and AJF20259 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I. Erkizia, E. Grau, M. Massanella, and J. Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling, and processing.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

  • Matuozzo, Daniela
  • Gut, Marta
  • Cobat, Aurélie
Background: We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15-20% of cases of life-threatening COVID-19 in unvaccinated patients. Therefore, the determinants of life-threatening COVID-19 remain to be identified in ~ 80% of cases. Methods: We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the 928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded. Results: No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI 1.5-528.7, P = 1.1 × 10-4) for biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR = 3.70[95%CI 1.3-8.2], P = 2.1 × 10-4). This enrichment was further strengthened by (1) adding the recently reported TYK2 and TLR7 COVID-19 loci, particularly under a recessive model (OR = 19.65[95%CI 2.1-2635.4], P = 3.4 × 10-3), and (2) considering as pLOF branchpoint variants with potentially strong impacts on splicing among the 15 loci (OR = 4.40[9%CI 2.3-8.4], P = 7.7 × 10-8). Finally, the patients with pLOF/bLOF variants at these 15 loci were significantly younger (mean age [SD] = 43.3 [20.3] years) than the other patients (56.0 [17.3] years; P = 1.68 × 10-5). Conclusions: Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old. Trial registration: ClinicalTrials.gov NCT04262921 NCT04259892 NCT04352348., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program COVIFERON (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir—Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 10101616. P Bastard was supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20–0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (Grant RECOVER WP 6). The COVIDeF study was supported by the French Ministry of Health, Fondation AP-HP et Programme Hospitalier de Recherche Clinique (PHRC COVID-19–20-0048) and was sponsored by APHP. Y.Z., O.M.D., L.D.N., H.C.S. are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. G.N. and A.N. are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020–36663, GecoBiomark. I Meyts is a Senior Clinical Investigator at the Research Foundation – Flanders, and is supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959). This work is supported by the Swiss National Science Foundation (grant # 310030L_197721 to JF). This work is supported by ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, and COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017–6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grant AJF202059 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I Erkizia, E Grau, M Massanella, and J Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling and processing.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

  • Bastard, Paul
  • Danish Blood Donor Study
  • Danish CHGE
  • Rigo Bonnin, Raúl
  • HGID Lab University of Hong Kong
  • Amsterdam UMC Covid-19 Biobank Investigators
  • St. James’s Hospital SARS CoV2 Interest group
  • Planas Obradors, Anna Maria
  • CONSTANCES Cohort
  • COVID Human Genetic Effort
  • Solanich, Xavier
  • 3C-Dijon Study
  • Milieu Intérieur Consortium
  • Cerba HealthCare
  • Morandeira-Rego, Francisco
  • Etablissement du Sang study group
  • NIAID Immune Response To Covid Group
  • COVID-STORM Clinicians University of Hong Kong
  • NH-COVAIR Study Group
  • Pujol Onofre, Aurora
  • French COVID Cohort Study Group
  • CoV-Contact Cohort
  • Imagine COVID Group
  • Casasnovas Pons, Carlos
  • Jordán García, Iolanda
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

  • Bastard, Paul
  • Gervais, Adrian
  • Le Voyer, Tom
  • Rosain, Jérémie
  • Philippot, Quentin
  • Manry, Jérémy
  • Michailidis, Eleftherios
  • Hoffmann, Hans-Heinrich
  • Eto, Shohei
  • García-Prat, Marina
  • Bizien, Lucy
  • Martínez-Picado, Javier
  • Raoult, Didier
  • Vasse, Marc
  • Gregersen, Peter K.
  • Piemonti, Lorenzo
  • Rodríguez-Gallego, Carlos
  • Notarangelo, Luigi D.
  • Su, Helen C.
  • Kisand, Kai
  • Luyt, Charles-Edouard
  • Kan, Nelli
  • Okada, Satoshi
  • Puel, Anne
  • Jouanguy, Emmanuelle
  • Rice, Charles M.
  • Tiberghien, Pierre
  • Zhang, Qian
  • Cobat, Aurélie
  • Abel, Laurent
  • Casanova, Jean-Laurent
  • Amador-Borrero, Blanca
  • Shcherbina, Anna
  • Gaudet, Alexandre
  • Poissy, Julien
  • Morel, Pascal
  • Richard, Pascale
  • Cognasse, Fabrice
  • Troya, Jesús
  • Trouillet-Assant, Sophie
  • Belot, Alexandre
  • Saker, Kahina
  • Garçon, Pierre
  • Lau, Yu-Lung
  • Rivière, Jacques G.
  • Lagier, Jean-Christophe
  • Gentile, Stephanie
  • Rosen, Lindsey B.
  • Shaw, Elana
  • Morio, Tomohiro
  • Tanaka, Junko
  • Dalmau, David
  • Tharaux, Pierre-Louis
  • Sene, Damien
  • Leung, Daniel
  • Stépanian, Alain
  • Mégarbane, Bruno
  • Triantafyllia, Vasiliki
  • Fekkar, Arnaud
  • Heath, James R.
  • Franco, José Luis
  • Anaya, Juan Manuel
  • Solé-Violán, Jordi
  • Imberti, Luisa
  • Biondi, Andrea
  • Coulongeat, Matthieu
  • Bonfanti, Paolo
  • Castagnoli, Riccardo
  • Delmonte, Ottavia M.
  • Zhang, Yu
  • Snow, Andrew L.
  • Holland, Steven M.
  • Biggs, Catherine M.
  • Moncada-Velez, Marcela
  • Arias, Andrés Augusto
  • Lorenzo, Lazaro
  • Marlet, Julien
  • Boucherit, Soraya
  • Coulibaly, Boubacar
  • Anglicheau, Dany
  • Planas, Anna M.
  • Haerynck, Filomeen
  • Duvlis, Sotirija
  • Nussbaum, Robert
  • Ozcelik, Tayfun
  • Keles, Sevgi
  • Bousfiha, Ahmed Aziz
  • Koning, Rutger
  • El Bakkouri, Jalila
  • Ramírez-Santana, Carolina
  • Paul, Stephanie
  • Pan-Hammarström, Qiang
  • Hammarström, Lennart
  • Dupont, Annabelle
  • Kurolap, Alina
  • Metz, Christine N.
  • Aiuti, Alessandro
  • Casari, Giorgio
  • Reyes, Luis Felipe
  • Lampasona, Vito
  • Ciceri, Fabio
  • Barreiros, Lucila
  • Domínguez-Garrido, Elena
  • Vidigal, Mateus
  • Zatz, Mayana
  • Beek, Diederik van der
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Stepanovskyy, Yuriy
  • Chauvineau-Grenier, Angélique
  • Boyarchuk, Oksana
  • Nukui, Yoko
  • Tsumura, Miyuki
  • Vidaur, Loreto
  • Tangye, Stuart G.
  • Burrel, Sonia
  • Duffy, Darragh
  • Quintana-Murci, Lluis
  • Klocperk, Adam
  • Venet, Fabienne
  • Parra-Martínez, Alba
  • Monneret, Guillaume
  • Nussenzweig, Michel C.
  • Arrestier, Romain
  • Boudhabhay, Idris
  • Baris, Hagit N.
  • Hagin, David
  • Wauters, Joost
  • Meyts, Isabelle
  • Dyer, Adam
  • Kennelly, Sean p.
  • Yang, Rui
  • Bourke, Nollaig
  • Halwani, Rabih
  • Sharif-Askari, Narjes Saheb
  • Dorgham, Karim
  • Sallette, Jerome
  • Mehlal-Sedkaoui, Souad
  • Alkhater, Suzan
  • Rigo-Bonnin, Raúl
  • Morandeira, Francisco
  • Roussel, Lucie
  • Haljasmägi, Liis
  • Vinh, Donald C.
  • Ostrowski, Sisse Rye
  • Condino-Neto, Antonio
  • Prando, Carolina
  • Bondarenko, Anastasiia
  • Spaan, András N.
  • Gilardin, Laurent
  • Fellay, Jacques
  • Lyonnet, Stanislas
  • Bilguvar, Kaya
  • Migaud, Mélanie
  • Lifton, Richard P.
  • Mane, Shrikant M.
  • HGID Lab
  • COVID Clinicians
  • COVID-STORM Clinicians
  • NIAID Immune Response to COVID Group
  • NH-COVAIR Study Group
  • Danish CHGE
  • Danish Blood Donor Study
  • St. James's Hospital SARS CoV2 Interest Group
  • Särekannu, Karita
  • French COVID Cohort Study Group
  • Imagine COVID Group
  • The Milieu Intérieur Consortium
  • CoV-Contact Cohort
  • Amsterdam UMC Covid-19 Biobank
  • COVID Human Genetic Effort
  • Constances Cohort
  • Dijon Study
  • Cerba HealthCare
  • Etablissement du Sang Study Group
  • Maslovskaja, Julia
  • Anderson, MarK S.
  • Boisson, Bertrand
  • Béziat, Vivien
  • Zhang, Shen-Ying
  • Andreakos, Evangelos
  • Hermine, Olivier
  • Pujol, Aurora
  • Peterson, Pärt
  • Mogensen, Trine
  • Rowen, Lee
  • Prost, Nicolas de
  • Mond, James
  • Debette, Stephanie
  • Lamballerie, Xavier de
  • Duval, Xavier
  • Mentré, France
  • Zins, Marie
  • Soler-Palacín, Pere
  • Colobran, Roger
  • Gorochov, Guy
  • Solanich, Xavier
  • Tandjaoui-Lambiotte, Yacine
  • Susen, Sophie
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 (coronavirus disease 2019) pneumonia but not in individuals with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or IFN-ω (100 pg/ml; in 1:10 dilutions of plasma) in 13.6% of 3595 patients with critical COVID-19, including 21% of 374 patients >80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1124 deceased patients (aged 20 days to 99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected individuals from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or IFN-ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of individuals carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over 80s and total fatal COVID-19 cases., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Awards (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS Nord-Sud (ANRS-COV05), ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 824110 (EASI-Genomics), the Square Foundation, Grandir–Fonds de solidarité pour l’Enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM; and the University of Paris. P.B. was supported by the FRM (EA20170638020). P.B., J.R., and T.L.V. were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt Schueller). Work in the Laboratory of Virology and Infectious Disease was supported by the NIH (P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1), a George Mason University Fast Grant, and the G. Harold and Leila Y. Mathers Charitable Foundation. The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). This work was also partly supported by the Intramural Research Program of the NIAID and NIDCR, NIH (grants ZIA AI001270 to L.D.N. and 1ZIAAI001265 to H.C.S.). This program is supported by the Agence Nationale de la Recherche (reference ANR-10-LABX-69-01). K.K.’s group was supported by the Estonian Research Council grants PRG117 and PRG377. R.H. was supported by an Al Jalila Foundation Seed Grant (AJF202019), Dubai, UAE, and a COVID-19 research grant (CoV19-0307) from the University of Sharjah, UAE. S.G.T. is supported by Investigator and Program Grants awarded by the National Health and Medical Research Council of Australia and a UNSW Sydney COVID Rapid Response Initiative Grant. L.I. reported funding from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”). L.I. and G. L. Marseglia reported funding from Regione Lombardia, Italy (project Risposta immune in pazienti con COVID-19 e co-morbidità). This research was partially supported by the Instituto de Salud Carlos III (COV20/0968). J.R.H. reported funding from Biomedical Advanced Research and Development Authority HHSO10201600031C. S.O. reports funding Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development, AMED (grant number JP20fk0108531). G.G. was supported by ANR Flash COVID-19 program and SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University iCOVID programs. The Three-City (3C) Study was conducted under a partnership agreement among the INSERM, the Victor Segalen Bordeaux 2 University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also supported by the Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Direction générale de la Santé, Mutuelle Générale de l’Education Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme “Cohortes et collections de données biologiques”. S. Debette was supported by the University of Bordeaux Initiative of Excellence. P.K.G. reports funding from the National Cancer Institute, NIH, under contract no. 75N91019D00024, task order no. 75N91021F00001. J.W. is supported by an FWO Fundamental Clinical Mandate (1833317N). Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. Work at Vall d’Hebron was also partly supported by research funding from Instituto de Salud Carlos III grant PI17/00660 cofinanced by the European Regional Development Fund (ERDF). C.R.-G. and colleagues of the Canarian Health System Sequencing Hub were supported by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334, Spanish Ministry for Science and Innovation RTC-2017-6471-1; AEI/FEDER, UE), Fundación DISA (OA18/017 and OA20/024), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). C.M.B. is supported by a MSFHR Health Professional-Investigator Award. P.Q.H. and L.H. were funded by the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650). Work at Y.-L.L.’s laboratory in the University of Hong Kong (HKU) was supported by the Society for the Relief of Disabled Children. MBBS/PhD study of D.L. in HKU was supported by the Croucher Foundation. J.L.F. was supported in part by the Coopération Scientifique France-Colciencias (ECOS-Nord/COLCIENCIAS/MEN/ICETEX (806-2018) and Colciencias contract 713-2016 (code 111574455633)]. A.K. was in part supported by grants NU20-05-00282 and NV18-05-00162 issued by the Czech Health Research Council and Ministry of Health, Czech Republic. L.P. was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (COVID-2020-12371617). I.M. is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies; by the KU Leuven C1 grant C16/18/007; by a VIB-GC PID grant; by the FWO frants G0C8517N, G0B5120N, and G0E8420N; and by the Jeffrey Modell Foundation. I.M. has received funding under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948959). E.A. received funding from the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). M.Vi received funding from the São Paulo Research Foundation (FAPESP) (grant number 2020/09702-1) and JBS SA (grant number 69004). The NH-COVAIR study group consortium was supported by a grant from the Meath Foundation, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

  • Manry, Jérémy
  • Bastard, Paul
  • Gervais, Adrian
  • Le Voyer, Tom
  • Rosain, Jérémie
  • Philippot, Quentin
  • Michailidis, Eleftherios
  • Hoffmann, Hans-Heinrich
  • Eto, Shohei
  • García-Prat, Marina
  • Bizien, Lucy
  • Raoult, Didier
  • Vasse, Marc
  • Gregersen, Peter K.
  • Piemonti, Lorenzo
  • Rodríguez-Gallego, Carlos
  • Notarangelo, Luigi D.
  • Su, Helen C.
  • Kisand, Kai
  • Okada, Satoshi
  • Luyt, Charles-Edouard
  • Lau, Yu-Lung
  • Puel, Anne
  • Jouanguy, Emmanuelle
  • Rice, Charles M.
  • Tiberghien, Pierre
  • Zhang, Qian
  • Casanova, Jean-Laurent
  • Abel, Laurent
  • Cobat, Aurélie
  • Amador-Borrero, Blanca
  • Gaudet, Alexandre
  • Leung, Daniel
  • Poissy, Julien
  • Morel, Pascal
  • Richard, Pascale
  • Cognasse, Fabrice
  • Troya, Jesús
  • Trouillet-Assant, Sophie
  • Belot, Alexandre
  • Saker, Kahina
  • Garçon, Pierre
  • Rivière, Jacques G.
  • Coulongeat, Matthieu
  • Lagier, Jean-Christophe
  • Gentile, Stephanie
  • Rosen, Lindsey B.
  • Shaw, Elana
  • Morio, Tomohiro
  • Tanaka, Junko
  • Dalmau, David
  • Tharaux, Pierre-Louis
  • Sene, Damien
  • Stépanian, Alain
  • Marlet, Julien
  • Mégarbane, Bruno
  • Triantafyllia, Vasiliki
  • Fekkar, Arnaud
  • Heath, James R.
  • Franco, José Luis
  • Anaya, Juan Manuel
  • Solé-Violán, Jordi
  • Imberti, Luisa
  • Biondi, Andrea
  • Bonfanti, Paolo
  • Koning, Rutger
  • Castagnoli, Riccardo
  • Delmonte, Ottavia M.
  • Zhang, Yu
  • Snow, Andrew L.
  • Holland, Steven M.
  • Biggs, Catherine M.
  • Moncada-Velez, Marcela
  • Arias, Andrés Augusto
  • Lorenzo, Lazaro
  • Boucherit, Soraya
  • Reyes, Luis Felipe
  • Anglicheau, Dany
  • Planas, Anna M.
  • Haerynck, Filomeen
  • Duvlis, Sotirija
  • Ozcelik, Tayfun
  • Keles, Sevgi
  • Bousfiha, Ahmed Aziz
  • El Bakkouri, Jalila
  • Ramírez-Santana, Carolina
  • Paul, Stephanie
  • Chauvineau-Grenier, Angélique
  • Pan-Hammarström, Qiang
  • Hammarström, Lennart
  • Dupont, Annabelle
  • Kurolap, Alina
  • Metz, Christine N.
  • Aiuti, Alessandro
  • Casari, Giorgio
  • Lampasona, Vito
  • Ciceri, Fabio
  • Barreiros, Lucila
  • Venet, Fabienne
  • Domínguez-Garrido, Elena
  • Vidigal, Mateus
  • Zatz, Mayana
  • Beek, Diederik van der
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Stepanovskyy, Yurii
  • Boyarchuk, Oksana
  • Nukui, Yoko
  • Tsumura, Miyuki
  • Monneret, Guillaume
  • Vidaur, Loreto
  • Tangye, Stuart G.
  • Burrel, Sonia
  • Duffy, Darragh
  • Quintana-Murci, Lluis
  • Klocperk, Adam
  • Kann, Nelli Y.
  • Shcherbina, Anna
  • Nussenzweig, Michel C.
  • Parra-Martínez, Alba
  • Arrestier, Romain
  • Boudhabhay, Idris
  • Baris-Feldman, Hagit
  • Hagin, David
  • Wauters, Joost
  • Meyts, Isabelle
  • Dyer, Adam H.
  • Kennelly, Sean P.
  • Bourke, Nollaig M.
  • Halwani, Rabih
  • Yang, Rui
  • Sharif-Askari, Fatemeh Saheb
  • Dorgham, Karim
  • Sallette, Jérôme
  • Mehlal-Sedkaoui, Souad
  • Alkhater, Suzan
  • Rigo-Bonnin, Raúl
  • Morandeira, Francisco
  • Roussel, Lucie
  • Vinh, Donald C.
  • Erikstrup, Christian
  • Haljasmägi, Liis
  • Condino-Neto, Antonio
  • Prando, Carolina
  • Bondarenko, Anastasiia
  • Spaan, András N.
  • Gilardin, Laurent
  • Fellay, Jacques
  • Lyonnet, Stanislas
  • Bilguvar, Kaya
  • Lifton, Richard P.
  • Mane, Shrikant M.
  • Migaud, Mélanie
  • HGID Lab
  • COVID Clinicians
  • COVID-STORM Clinicians
  • NIAID Immune Response to COVID Group
  • NH-COVAIR Study Group
  • Danish CHGE
  • Danish Blood Donor Study
  • St. James's Hospital SARS CoV2 Interest Group
  • French COVID Cohort Study Group
  • Imagine COVID Group
  • Särekannu, Karita
  • The Milieu Intérieur Consortium
  • CoV-Contact Cohort
  • Amsterdam UMC Covid-19 Biobank Investigators
  • COVID Human Genetic Effort
  • CP-COVID-19 Group
  • Constances Cohort
  • 3C-Dijon Study
  • Cerba Health-Care
  • Etablissement Français du Sang Study group
  • Anderson, MarK S.
  • Maslovskaja, Julia
  • Boisson, Bertrand
  • Béziat, Vivien
  • Zhang, Shen-Ying
  • Andreakos, Evangelos
  • Hermine, Olivier
  • Pujol, Aurora
  • Peterson, Pärt
  • Mogensen, Trine
  • Rowen, Lee
  • Mond, James
  • Prost, Nicolas de
  • Debette, Stephanie
  • Lamballerie, Xavier de
  • Burdet, Charles
  • Bouadma, Lila
  • Zins, Marie
  • Soler-Palacín, Pere
  • Colobran, Roger
  • Gorochov, Guy
  • Solanich, Xavier
  • Susen, Sophie
  • Tandjaoui-Lambiotte, Yacine
  • Martínez-Picado, Javier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals <70 y and ≥70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals <40 y old to 26.7% (20.3 to 35.2) for those ≥80 y old for autoantibodies neutralizing IFN-α2 or IFN-ω, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-α2 and IFN-ω. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute; The Rockefeller University; the St. Giles Foundation; the NIH (Grants R01AI088364 and R01AI163029); the National Center for Advancing Translational Sciences; NIH Clinical and Translational Science Awards program (Grant UL1 TR001866); a Fast Grant from Emergent Ventures; Mercatus Center at George Mason University; the Yale Center for Mendelian Genomics and the Genome Sequencing Program Coordinating Center funded by the National Human Genome Research Institute (Grants UM1HG006504 and U24HG008956); the Yale High Performance Computing Center (Grant S10OD018521); the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the French National Research Agency (ANR) under the “Investments for the Future” program (Grant ANR-10-IAHU-01); the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (Grant ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM) (Grant EQU201903007798); the French Agency for Research on AIDS and Viral hepatitis (ANRS) Nord-Sud (Grant ANRS-COV05); the ANR GENVIR (Grant ANR-20-CE93-003), AABIFNCOV (Grant ANR-20-CO11-0001), CNSVIRGEN (Grant ANR-19-CE15-0009-01), and GenMIS-C (Grant ANR-21-COVR-0039) projects; the Square Foundation; Grandir–Fonds de solidarité pour l’Enfance; the Fondation du Souffle; the SCOR Corporate Foundation for Science; The French Ministry of Higher Education, Research, and Innovation (Grant MESRI-COVID-19); Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM; and the University Paris Cité. P. Bastard was supported by the FRM (Award EA20170638020). P. Bastard., J.R., and T.L.V. were supported by the MD-PhD program of the Imagine Institute (with the support of Fondation Bettencourt Schueller). Work at the Neurometabolic Disease lab received funding from Centre for Biomedical Research on Rare Diseases (CIBERER) (Grant ACCI20-767) and the European Union's Horizon 2020 research and innovation program under grant agreement 824110 (EASI Genomics). Work in the Laboratory of Virology and Infectious Disease was supported by the NIH (Grants P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1), a George Mason University Fast Grant, and the G. Harold and Leila Y. Mathers Charitable Foundation. The Infanta Leonor University Hospital supported the research of the Department of Internal Medicine and Allergology. The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (Grant RECOVER WP 6). This work was also partly supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases and the National Institute of Dental and Craniofacial Research, NIH (Grants ZIA AI001270 to L.D.N. and 1ZIAAI001265 to H.C.S.). This program is supported by the Agence Nationale de la Recherche (Grant ANR-10-LABX-69-01). K.K.’s group was supported by the Estonian Research Council, through Grants PRG117 and PRG377. R.H. was supported by an Al Jalila Foundation Seed Grant (Grant AJF202019), Dubai, United Arab Emirates, and a COVID-19 research grant (Grant CoV19-0307) from the University of Sharjah, United Arab Emirates. S.G.T. is supported by Investigator and Program Grants awarded by the National Health and Medical Research Council of Australia and a University of New South Wales COVID Rapid Response Initiative Grant. L.I. reports funding from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”). This research was partially supported by the Instituto de Salud Carlos III (Grant COV20/0968). J.R.H. reports funding from Biomedical Advanced Research and Development Authority (Grant HHSO10201600031C). S.O. reports funding from Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development (Grant JP20fk0108531). G.G. was supported by the ANR Flash COVID-19 program and SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University iCOVID programs. The 3C Study was conducted under a partnership agreement between INSERM, Victor Segalen Bordeaux 2 University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also supported by the Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Direction générale de la Santé, Mutuelle Générale de l’Education Nationale, Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Program “Cohortes et collections de données biologiques.” S. Debette was supported by the University of Bordeaux Initiative of Excellence. P.K.G. reports funding from the National Cancer Institute, NIH, under Contract 75N91019D00024, Task Order 75N91021F00001. J.W. is supported by a Research Foundation - Flanders (FWO) Fundamental Clinical Mandate (Grant 1833317N). Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. Work at Vall d’Hebron was also partly supported by research funding from Instituto de Salud Carlos III Grant PI17/00660 cofinanced by the European Regional Development Fund (ERDF/FEDER). C.R.-G. and colleagues from the Canarian Health System Sequencing Hub were supported by the Instituto de Salud Carlos III (Grants COV20_01333 and COV20_01334), the Spanish Ministry for Science and Innovation (RTC-2017-6471-1; AEI/FEDER, European Union), Fundación DISA (Grants OA18/017 and OA20/024), and Cabildo Insular de Tenerife (Grants CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). T.H.M. was supported by grants from the Novo Nordisk Foundation (Grants NNF20OC0064890 and NNF21OC0067157). C.M.B. is supported by a Michael Smith Foundation for Health Research Health Professional-Investigator Award. P.Q.H. and L. Hammarström were funded by the European Union’s Horizon 2020 research and innovation program (Antibody Therapy Against Coronavirus consortium, Grant 101003650). Work at Y.-L.L.’s laboratory in the University of Hong Kong (HKU) was supported by the Society for the Relief of Disabled Children. MBBS/PhD study of D.L. in HKU was supported by the Croucher Foundation. J.L.F. was supported in part by the Evaluation-Orientation de la Coopération Scientifique (ECOS) Nord - Coopération Scientifique France-Colombie (ECOS-Nord/Columbian Administrative department of Science, Technology and Innovation [COLCIENCIAS]/Colombian Ministry of National Education [MEN]/Colombian Institute of Educational Credit and Technical Studies Abroad [ICETEX, Grant 806-2018] and Colciencias Contract 713-2016 [Code 111574455633]). A. Klocperk was, in part, supported by Grants NU20-05-00282 and NV18-05-00162 issued by the Czech Health Research Council and Ministry of Health, Czech Republic. L.P. was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (Grant COVID-2020-12371617). I.M. is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies (PID); by the Katholieke Universiteit Leuven C1 Grant C16/18/007; by a Flanders Institute for Biotechnology-Grand Challenges - PID grant; by the FWO Grants G0C8517N, G0B5120N, and G0E8420N; and by the Jeffrey Modell Foundation. I.M. has received funding under the European Union’s Horizon 2020 research and innovation program (Grant Agreement 948959). E.A. received funding from the Hellenic Foundation for Research and Innovation (Grant INTERFLU 1574). M. Vidigal received funding from the São Paulo Research Foundation (Grant 2020/09702-1) and JBS SA (Grant 69004). The NH-COVAIR study group consortium was supported by a grant from the Meath Foundation., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

  • Bastard, Paul
  • Danish Blood Donor Study
  • Danish CHGE
  • Rigo Bonnin, Raúl
  • HGID Lab University of Hong Kong
  • Amsterdam UMC Covid-19 Biobank Investigators
  • St. James’s Hospital SARS CoV2 Interest group
  • Planas Obradors, Anna Maria
  • CONSTANCES Cohort
  • COVID Human Genetic Effort
  • Solanich, Xavier
  • 3C-Dijon Study
  • Milieu Intérieur Consortium
  • Cerba HealthCare
  • Morandeira-Rego, Francisco
  • Etablissement du Sang study group
  • NIAID Immune Response To Covid Group
  • COVID-STORM Clinicians University of Hong Kong
  • NH-COVAIR Study Group
  • Pujol Onofre, Aurora
  • French COVID Cohort Study Group
  • CoV-Contact Cohort
  • Imagine COVID Group
  • Casasnovas Pons, Carlos
  • Jordán García, Iolanda
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

  • Marchal, Astrid
  • COVID Clinicians
  • Bolze, Alexandre
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B∗15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the United States (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B∗15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections studied, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer's Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (Equation 201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 101057100 (UNDINE), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of business in EMEA, and the General Atlantic Foundation, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. A.N.S. is supported by European Union’s Horizon Health research and innovation program under grant agreement No. 101057100, project UNDINE. S.G.T. is supported by an Investigator Grant awarded by the National Health and Medical Research Council of Australia, and a University of New South Wales Sydney COVID Rapid Response Initiative grant. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 10101616. The French COVID Cohort study group was sponsored by Inserm and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, European Commission (Grant RECOVER WP 6). The COVIDeF study group was supported by the French Ministry of Health and Fondation AP-HP Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0048). Y.Z. is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. This project has received funding from the Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959), the Swiss National Science Foundation (grant # 310030L_197721 to J.F.), and ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grants AJF202019 and AJF20259 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I. Erkizia, E. Grau, M. Massanella, and J. Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling, and processing.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

  • Matuozzo, Daniela
  • Gut, Marta
  • Cobat, Aurélie
Background: We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15-20% of cases of life-threatening COVID-19 in unvaccinated patients. Therefore, the determinants of life-threatening COVID-19 remain to be identified in ~ 80% of cases. Methods: We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the 928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded. Results: No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI 1.5-528.7, P = 1.1 × 10-4) for biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR = 3.70[95%CI 1.3-8.2], P = 2.1 × 10-4). This enrichment was further strengthened by (1) adding the recently reported TYK2 and TLR7 COVID-19 loci, particularly under a recessive model (OR = 19.65[95%CI 2.1-2635.4], P = 3.4 × 10-3), and (2) considering as pLOF branchpoint variants with potentially strong impacts on splicing among the 15 loci (OR = 4.40[9%CI 2.3-8.4], P = 7.7 × 10-8). Finally, the patients with pLOF/bLOF variants at these 15 loci were significantly younger (mean age [SD] = 43.3 [20.3] years) than the other patients (56.0 [17.3] years; P = 1.68 × 10-5). Conclusions: Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old. Trial registration: ClinicalTrials.gov NCT04262921 NCT04259892 NCT04352348., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program COVIFERON (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir—Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 10101616. P Bastard was supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20–0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (Grant RECOVER WP 6). The COVIDeF study was supported by the French Ministry of Health, Fondation AP-HP et Programme Hospitalier de Recherche Clinique (PHRC COVID-19–20-0048) and was sponsored by APHP. Y.Z., O.M.D., L.D.N., H.C.S. are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. G.N. and A.N. are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020–36663, GecoBiomark. I Meyts is a Senior Clinical Investigator at the Research Foundation – Flanders, and is supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959). This work is supported by the Swiss National Science Foundation (grant # 310030L_197721 to JF). This work is supported by ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, and COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017–6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grant AJF202059 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I Erkizia, E Grau, M Massanella, and J Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling and processing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years and account for ~ 20% of COVID-19 deaths

  • Bastard, Paul|||0000-0002-5926-8437
  • Gervais, Adrian|||0000-0002-1083-5787
  • Le Voyer, Tom|||0000-0002-7253-3135
  • Rosain, Jérémie|||0000-0002-2822-161X
  • Philippot, Quentin
  • Manry, Jeremy|||0000-0001-5998-2051
  • Michailidis, Eleftherios|||0000-0002-9907-4346
  • Hoffmann, Hans-Heinrich|||0000-0003-0554-0244
  • Eto, Shohei|||0000-0002-2885-7490
  • Garcia-Prat, Marina|||0000-0001-5387-1908
  • Bizien, Lucy|||0000-0001-9163-9122
  • Parra-Martínez, Alba|||0000-0002-9564-8912
  • Yang, Rui|||0000-0003-4427-2158
  • Haljasmägi, Liis|||0000-0001-7162-9808
  • Migaud, Mélanie|||0000-0003-3062-1214
  • Särekannu, Karita|||0000-0002-5984-668X
  • Maslovskaja, Julia
  • de Prost, Nicolas|||0000-0002-4833-4320
  • Tandjaoui-Lambiotte redondo, Yacine|||0000-0003-1123-4788
  • Luyt, Charles-Edouard|||0000-0001-7424-2705
  • Amador Borrero, Blanca|||0000-0001-6170-8721
  • Gaudet, Alexandre
  • Poissy, Julien|||0000-0001-6017-5353
  • Morel, Pascal
  • Richard, Pascale|||0000-0003-1864-3824
  • Cognasse, Fabrice|||0000-0001-8041-928X
  • Troya, Jesús|||0000-0001-7323-114X
  • Trouillet-Assant, Sophie|||0000-0001-6439-4705
  • Belot, Alexandre|||0000-0003-4902-5332
  • Saker, Kahina|||0000-0001-8825-5400
  • Garçon, Pierre
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Lagier, Jean-Christophe
  • Gentile, Stéphanie|||0000-0003-3858-9503
  • Rosen, Lindsey|||0000-0001-5894-3878
  • Shaw, Elana|||0000-0001-9265-8026
  • Morio, Tomohiro
  • Tanaka, Junko
  • Dalmau, David|||0000-0003-1936-478X
  • Tharaux, Pierre-Louis|||0000-0002-6062-5905
  • Sene, Damien
  • Stepanian, Alain|||0000-0002-2942-0901
  • Mégarbane, Bruno|||0000-0002-2522-2764
  • Triantafyllia, Vasiliki|||0000-0001-5832-4014
  • Fekkar, Arnaud|||0000-0001-9954-075X
  • Heath, James R.|||0000-0001-5356-4385
  • Franco, Jose|||0000-0001-5664-6415
  • Anaya, Juan-Manuel|||0000-0002-6444-1249
  • Solé-Violán, Jordi
  • Imberti, Luisa|||0000-0002-2075-8391
  • Biondi, Andrea
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Castagnoli, Riccardo|||0000-0003-0029-9383
  • Delmonte, Ottavia M.
  • Zhang, Yu|||0000-0002-0332-0013
  • Snow, Andrew|||0000-0002-8728-6691
  • Holland, Steven|||0000-0003-3207-5464
  • Biggs, Catherine|||0000-0002-4363-2660
  • Moncada-Velez, Marcela|||0000-0002-3073-5345
  • Arias, Andrés Augusto|||0000-0002-9478-8403
  • Lorenzo, Lazaro|||0000-0001-6648-8684
  • Boucherit, Soraya|||0000-0002-8819-7594
  • Coulibaly, Boubacar
  • Anglicheau, Dany|||0000-0001-5793-6174
  • Planas, Anna Maria|||0000-0002-6147-1880
  • Haerynck, Filomeen|||0000-0001-9161-7361
  • Duvlis, Sotirija|||0000-0001-8587-7386
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Keles, Sevgi|||0000-0001-7344-8947
  • Bousfiha, Ahmed Aziz|||0000-0002-5011-9873
  • El Bakkouri, Jalila|||0000-0003-2303-3369
  • Ramirez-Santana, Carolina|||0000-0003-2137-4899
  • Paul, Stephane|||0000-0002-8830-4273
  • Pan-Hammarström, Qiang|||0000-0003-1990-8804
  • Hammarström, Lennart|||0000-0002-8635-9609
  • Dupont, Annabelle|||0000-0002-1554-9931
  • Kurolap, Alina|||0000-0002-7005-3621
  • Metz, Christine N.|||0000-0002-1013-1691
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Casari, Giorgio|||0000-0002-0115-8980
  • Lampasona, Vito|||0000-0001-5162-8445
  • Ciceri, Fabio|||0000-0003-0873-0123
  • Barreiros, Lucila|||0000-0002-9818-2345
  • Domínguez-Garrido, Elena|||0000-0002-2066-0511
  • Vidigal, Mateus de Castro|||0000-0002-8895-652X
  • Zatz, Mayana|||0000-0003-3970-8025
  • van de Beek, Diederik|||0000-0002-4571-044X
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Stepanovskyy, Yuriy|||0000-0001-6339-5490
  • Boyarchuk, Oksana|||0000-0002-1234-0040
  • Nukui, Yoko|||0000-0002-6123-5212
  • Tsumura, Miyuki
  • Vidaur, Loreto|||0000-0002-6720-4900
  • Tangye, Stuart|||0000-0002-5360-5180
  • Burrel, Sonia|||0000-0002-7783-2601
  • Duffy, Darragh|||0000-0002-8875-2308
  • Quintana-Murci, Lluis|||0000-0003-2429-6320
  • Klocperk, Adam
  • Kann, Nelli Y.|||0000-0003-3564-6496
  • Shcherbina, Anna|||0000-0002-3113-4939
  • Lau, Yu Lung|||0000-0002-4780-0289
  • Leung, Daniel|||0000-0002-9360-6233
  • Coulongeat, Matthieu|||0000-0003-1986-3546
  • Marlet, Julien|||0000-0002-8645-8703
  • Koning, Rutger|||0000-0003-3128-5072
  • Reyes, Luis Felipe|||0000-0003-1172-6539
  • Chauvineau-Grenier, Angélique
  • Venet, Fabienne|||0000-0003-0462-4235
  • Monneret, Guillaume|||0000-0002-9961-5739
  • Nussenzweig, Michel|||0000-0003-0592-8564
  • Arrestier, Romain
  • Boudhabhay, Idris
  • Baris-Feldman, Hagit|||0000-0003-4065-7560
  • Hagin, David|||0000-0003-2702-1031
  • Wauters, Joost|||0000-0002-5983-3897
  • Meyts, Isabelle|||0000-0003-1214-0302
  • Dyer, Adam|||0000-0003-1356-510X
  • Kennelly, Sean P.
  • Bourke, Nollaig|||0000-0003-4313-6859
  • Halwani, Rabih|||0000-0002-6516-7771
  • Sharif-Askari, Narjes Saheb|||0000-0003-0482-6777
  • Dorgham, Karim|||0000-0001-9539-3203
  • Sallette, Jérome
  • Sedkaoui, Souad Mehlal
  • AlKhater, Suzan|||0000-0001-7315-6581
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Morandeira Rego, Francisco|||0000-0002-6099-1040
  • Roussel, Lucie|||0000-0001-5355-702X
  • Vinh, Donald C.|||0000-0003-1347-7767
  • Ostrowski, Sisse Rye|||0000-0001-5288-3851
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Prando, Carolina|||0000-0002-9570-9770
  • Bonradenko, Anastasiia
  • Spaan, András|||0000-0001-5981-7259
  • Gilardin, Laurent|||0000-0001-9212-0859
  • Fellay, Jacques|||0000-0002-8240-939X
  • Lyonnet, Stanislas
  • Bilguvar, Kaya|||0000-0002-7313-7652
  • Lifton, Richard P.
  • Mane, Shrikant|||0000-0002-3267-5139
  • Anderson, Mark|||0000-0002-3093-4758
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Béziat, Vivien|||0000-0002-4020-824X
  • Zhang, Shen-Ying|||0000-0002-9449-3672
  • Vandreakos, Evangelos|||0000-0001-5536-1661
  • Hermine, Olivier|||0000-0003-2574-3874
  • Pujol, Aurora|||0000-0002-9606-0600
  • Peterson, Pärt|||0000-0001-6755-791X
  • Mogensen, Trine Hyrup|||0000-0002-1853-9704
  • Rowen, Lee
  • Mond, James
  • Debette, Stéphanie|||0000-0001-8675-7968
  • De Lamballerie, Xavier|||0000-0001-7895-2720
  • Duval, Xavier
  • Mentré, France
  • Zins, Marie|||0000-0002-4540-4282
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Gorochov, Guy|||0000-0003-2097-9677
  • Solanich, Xavier|||0000-0002-2572-2187
  • Susen, Sophie|||0000-0001-5953-163X
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Raoult, Didier
  • Vasse, Marc
  • Gregersen, Peter K.|||0000-0003-1613-1518
  • Piemonti, Lorenzo|||0000-0002-2172-2198
  • Rodríguez-Gallego, Carlos|||0000-0002-4344-8644
  • Notarangelo, Luigi|||0000-0002-8335-0262
  • Su, Helen C.|||0000-0002-5582-9110
  • Kisand, Kai|||0000-0002-5426-4648
  • Okada, Satoshi|||0000-0002-4622-5657
  • Puel, Anne|||0000-0003-2603-0323
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Rice, Charles M.|||0000-0003-3087-8079
  • Tiberghien, Pierre|||0000-0002-9310-8322
  • Zhang, Qian|||0000-0002-9040-3289
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Abel, Laurent|||0000-0001-7016-6493
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients.